Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol

The application of personalized medicine in patients with first-episode psychosis (FEP) requires tools for classifying patients according to their response to treatment, considering both treatment efficacy and toxicity. However, several limitations have hindered its translation into clinical practic...

Descripción completa

Detalles Bibliográficos
Autores: Mas, Sergi, Julià, Laura, Cuesta, Manuel J., Crespo Facorro, Benedicto, Vázquez-Bourgon, Javier, Spuch, Carlos, González-Pinto, Ana, Ibáñez, Ángela, Usall, Judith, Romero-López-Alberca, Cristina, Catalan, Ana, Mané, Anna, Bernardo, Miquel
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/173085
Acceso en línea:https://hdl.handle.net/11441/173085
https://doi.org/10.3389/fpsyt.2024.1497565
Access Level:acceso abierto
Palabra clave:personalized medicine
antipsychotic
prediction
psychosis
Pharmacogenetics
id ES_618ff2e6740c1bd671f129adc38fecc7
oai_identifier_str oai:idus.us.es:11441/173085
network_acronym_str ES
network_name_str España
repository_id_str
spelling Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocolMas, SergiJulià, LauraCuesta, Manuel J.Crespo Facorro, BenedictoVázquez-Bourgon, JavierSpuch, CarlosGonzález-Pinto, AnaIbáñez, ÁngelaUsall, JudithRomero-López-Alberca, CristinaCatalan, AnaMané, AnnaBernardo, Miquelpersonalized medicineantipsychoticpredictionpsychosisPharmacogeneticsThe application of personalized medicine in patients with first-episode psychosis (FEP) requires tools for classifying patients according to their response to treatment, considering both treatment efficacy and toxicity. However, several limitations have hindered its translation into clinical practice. Here, we describe the rationale, aims and methodology of Applied Pharmacogenetics to Predict Response to Treatment of First Psychotic Episode (the FarmaPRED-PEP project), which aims to develop and validate predictive algorithms to classify FEP patients according to their response to antipsychotics, thereby allowing the most appropriate treatment strategy to be selected. These predictors will integrate, through machine learning techniques, pharmacogenetic (measured as polygenic risk scores) and epigenetic data together with clinical, sociodemographic, environmental, and neuroanatomical data. To do this, the FarmaPRED-PEP project will use data from two already recruited cohorts: the PEPS cohort from the “Genotype-Phenotype Interaction and Environment. Application to a Predictive Model in First Psychotic Episodes” study (the PEPs study from the Spanish abbreviation) (N=335) and the PAFIP cohort from “Clinical Program on Early Phases of Psychosis” (PAFIP from the Spanish abbreviation) (N = 350). These cohorts will be used to create the predictor, which will then be validated in a new cohort, the FarmaPRED cohort (N = 300). The FarmaPRED-PEP project has been designed to overcome several of the limitations identified in pharmacogenetic studies in psychiatry: (1) the sample size; (2) the phenotype heterogeneity and its definition; (3) the complexity of the phenotype and (4) the gender perspective. The global reach of the FarmaPRED-PEP project is to facilitate the effective deployment of precision medicine in national health systems.Frontiers Media SAPsiquiatríaCTS1086: Psiquiatría TraslacionalInstituto de Salud Carlos III2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/173085https://doi.org/10.3389/fpsyt.2024.1497565reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésFrontiers In Psychiatry, 1497565.https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1497565/fullinfo:eu-repo/semantics/openAccessoai:idus.us.es:11441/1730852026-06-17T12:51:07Z
dc.title.none.fl_str_mv Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
title Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
spellingShingle Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
Mas, Sergi
personalized medicine
antipsychotic
prediction
psychosis
Pharmacogenetics
title_short Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
title_full Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
title_fullStr Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
title_full_unstemmed Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
title_sort Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
dc.creator.none.fl_str_mv Mas, Sergi
Julià, Laura
Cuesta, Manuel J.
Crespo Facorro, Benedicto
Vázquez-Bourgon, Javier
Spuch, Carlos
González-Pinto, Ana
Ibáñez, Ángela
Usall, Judith
Romero-López-Alberca, Cristina
Catalan, Ana
Mané, Anna
Bernardo, Miquel
author Mas, Sergi
author_facet Mas, Sergi
Julià, Laura
Cuesta, Manuel J.
Crespo Facorro, Benedicto
Vázquez-Bourgon, Javier
Spuch, Carlos
González-Pinto, Ana
Ibáñez, Ángela
Usall, Judith
Romero-López-Alberca, Cristina
Catalan, Ana
Mané, Anna
Bernardo, Miquel
author_role author
author2 Julià, Laura
Cuesta, Manuel J.
Crespo Facorro, Benedicto
Vázquez-Bourgon, Javier
Spuch, Carlos
González-Pinto, Ana
Ibáñez, Ángela
Usall, Judith
Romero-López-Alberca, Cristina
Catalan, Ana
Mané, Anna
Bernardo, Miquel
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Psiquiatría
CTS1086: Psiquiatría Traslacional
Instituto de Salud Carlos III
dc.subject.none.fl_str_mv personalized medicine
antipsychotic
prediction
psychosis
Pharmacogenetics
topic personalized medicine
antipsychotic
prediction
psychosis
Pharmacogenetics
description The application of personalized medicine in patients with first-episode psychosis (FEP) requires tools for classifying patients according to their response to treatment, considering both treatment efficacy and toxicity. However, several limitations have hindered its translation into clinical practice. Here, we describe the rationale, aims and methodology of Applied Pharmacogenetics to Predict Response to Treatment of First Psychotic Episode (the FarmaPRED-PEP project), which aims to develop and validate predictive algorithms to classify FEP patients according to their response to antipsychotics, thereby allowing the most appropriate treatment strategy to be selected. These predictors will integrate, through machine learning techniques, pharmacogenetic (measured as polygenic risk scores) and epigenetic data together with clinical, sociodemographic, environmental, and neuroanatomical data. To do this, the FarmaPRED-PEP project will use data from two already recruited cohorts: the PEPS cohort from the “Genotype-Phenotype Interaction and Environment. Application to a Predictive Model in First Psychotic Episodes” study (the PEPs study from the Spanish abbreviation) (N=335) and the PAFIP cohort from “Clinical Program on Early Phases of Psychosis” (PAFIP from the Spanish abbreviation) (N = 350). These cohorts will be used to create the predictor, which will then be validated in a new cohort, the FarmaPRED cohort (N = 300). The FarmaPRED-PEP project has been designed to overcome several of the limitations identified in pharmacogenetic studies in psychiatry: (1) the sample size; (2) the phenotype heterogeneity and its definition; (3) the complexity of the phenotype and (4) the gender perspective. The global reach of the FarmaPRED-PEP project is to facilitate the effective deployment of precision medicine in national health systems.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/173085
https://doi.org/10.3389/fpsyt.2024.1497565
url https://hdl.handle.net/11441/173085
https://doi.org/10.3389/fpsyt.2024.1497565
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Frontiers In Psychiatry, 1497565.
https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1497565/full
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media SA
publisher.none.fl_str_mv Frontiers Media SA
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409425943429120
score 15,812429

Similares en LA Referencia